GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Imunon IMNN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.88

+4.51%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Imunon

From its filings with the US Securities and Exchange Commission

SEC filings

Imunon is based in Lawrenceville, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IMNN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $500,000.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
27 Oct 1993
Employees
31
Website
imunon.com ↗
Head office
997 LENOX DRIVE, LAWRENCEVILLE, NJ, 08648
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Michael TardugnoExecutive Chairman of the Board, since 2007$734,810
  • Dr. Stacy LindborgPresident, Chief Executive Officer, Director, since 2021$1.2m
  • Ms. Kimberly GraperInterim Chief Financial Officer
  • Dr. Khursheed AnwerExecutive Vice President, Chief Scientific Officer$741,680
  • Ms. Susan EylwardGeneral Counsel, Corporate Secretary
  • Dr. Douglas FallerChief Medical Officer
  • Dr. Donald BraunIndependent Director$58,962
  • Mr. James DentzerIndependent Director$63,983
  • Mr. Frederick FritzIndependent Director$106,728
  • Ms. Christine PellizzariIndependent Director$54,495

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Imunon Inc has two platform technologies: TheraPlas and PLACCINE.
  • The company focuses on advancing treatments that harness the body's natural mechanisms.
  • Imunon has a lead clinical program, IMNN-001, for advanced ovarian cancer treatment.

Weaknesses

  • The company has only 31 employees, indicating a small operational scale.
  • Imunon is a clinical stage oncology drug company with limited commercialization experience.
  • The company's lead program is focused on a single cancer type, ovarian cancer.

Opportunities

  • The PLACCINE platform could be expanded to develop nucleic acid vaccines for other infectious diseases.
  • Preclinical studies on a SARS-CoV-2 vaccine may validate the PLACCINE platform for broader applications.
  • Advancements in nucleic acid-based therapies could attract additional investment.

Threats

  • Clinical stage companies face high risks of trial failures and regulatory hurdles.
  • The focus on a single cancer type may limit market opportunities.
  • Competition in the oncology drug development space is intense.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.